- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT06657859
Otevřená rozšiřující studie k posouzení GLM101 u pacientů s PMM2-CDG
Fáze 2, otevřená rozšiřující studie k posouzení bezpečnosti a účinnosti GLM101 podávaného nitrožilně účastníkům s PMM2-CDG
The goal of this clinical trial is to provide continued access to GLM101 to treat PMM2-CDG in people who have previously received GLM101 in other trials and learn about the long term effect of GLM101. Participants will complete weekly infusions of GLM101 at the same dose level received in previous trials.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
This is a phase 2 open-label clinical study of GLM101 in patients with PMM2-CDG who have previously participated in a study of GLM101. This study is designed to monitor long-term safety and treatment effect of GLM101 and provide continued access to study treatment. Participants will receive 30 mg/kg. Dose levels may be adjusted to lower doses or higher doses based on available data that demonstrates a change to be safe and favorable. Among other assessments, participants will be asked to complete questionnaires to evaluate changes in ataxia and quality of life.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
-
Paris, Francie, 75015
- AP-HP Hopital Universitaire Necker-Enfants Malades
-
-
-
-
-
Catania, Itálie, 95124
- Azienda Ospedaliero Universitaria Policlinico G. Rodolico-San Marco - Presidio Ospedaliero G. Rodolico
-
Pisa, Itálie, 56126
- Azienda Ospedaliero Universitaria Pisana
-
-
-
-
-
Münster, Německo, 48149
- Universitaetsklinikum Münster
-
-
-
-
-
Porto, Portugalsko, 4099-001
- Unidade Local de Saúde de Santo António, E.P.E
-
-
-
-
-
Birmingham, Spojené království, B4 6NH
- Birmingham Children's Hospital
-
London, Spojené království, WC1N 3JH
- Great Ormond Street Hospital for Children
-
-
-
-
Minnesota
-
Minneapolis, Minnesota, Spojené státy, 55455
- University of Minnesota
-
-
New York
-
New York, New York, Spojené státy, 10029
- The Icahn School of Medicine at Mount Sinai
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19104
- The Children's Hospital of Philadelphia (CHOP)
-
-
Washington
-
Seattle, Washington, Spojené státy, 98105
- Seattle Children's Hospital
-
-
-
-
-
Prague, Česko, 128 08
- Vseobecna fakultni nemocnice v Praze
-
-
-
-
-
Esplugues de Llobregat, Španělsko, 08950
- Hospital Sant Joan de Déu
-
Madrid, Španělsko, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Španělsko, 28041
- Hospital Universitario 12 de Octubre - Unidad Pediatrica de Investigacion y Ensayos Clinicos (UPIC)
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Is willing and able to provide informed consent/assent, directly or through a legally authorized representative.
-
Has successfully completed the Treatment Period with GLM101 in a previous clinical study.
-
At least 2 years of age, at the time of signing the informed consent form (ICF).
-
Molecularly confirmed diagnosis of PMM2-CDG. Diagnosis is defined as biallelic pathogenic and/or likely pathogenic variants, or, in the case of variants of uncertain pathogenicity, demonstration of bi-allelic variants AND phosphomannomutase-2 (PMM2) enzyme activity consistent with a diagnosis of PMM2-CDG. Historical diagnosis including from a prior parent trial is permitted;
-
Male or female participant has appropriate measures in place to prevent pregnancy:
- If the participant is a female of childbearing potential (i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile (permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy)) or becomes of childbearing potential during the study, she must not be pregnant (confirmed by a negative serum pregnancy test), is using a medically accepted method of contraception (abstinence, a hormonal contraceptive associated with inhibition of ovulation in conjunction with a barrier method, or use of an intrauterine device), and must agree to continue using this method for 50 days after the last infusion of GLM101. Note: True abstinence: defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant. Periodic abstinence (such as calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
- If the participant is a female of non-childbearing potential, she must be pre-pubertal, surgically sterile, or must have an ovarian dysfunction confirmed by a follicle stimulating hormone (FSH) >40 IU/L and absence of menses for 12 months without an alternative medical cause.
- If the participant is a sexually active (or becomes sexually active during the study) male with female partners, the sexually mature, nonsterile male participant agrees to use a medically acceptable method of contraception (abstinence, the partner taking a hormonal contraceptive in conjunction with a male condom, or use by the partner of an intrauterine device with a male condom) and agrees to continue using this method for 50 days after the last infusion of GLM101. Males are considered surgically sterile if they have undergone bilateral orchiectomy or vasectomy at least 3 months prior to Screening.
-
If the participant is male, he must agree to refrain from donating sperm during the study and 50 days after the last infusion of GLM101.
-
Is willing and able to comply with this protocol.
Exclusion Criteria:
Participants who meet any of the following criteria will be excluded from participation in the study:
- Has any other condition that would, in the opinion of the Investigator, potentially compromise the safety or compliance of the participant or preclude the participant's successful completion of the study.
- Diagnosis of congenital disorder of glycosylation (CDG) other than PMM2; Diagnosis is defined as biallelic pathogenic and/or likely pathogenic variants, or, in the case of variants of uncertain pathogenicity, demonstration of bi-allelic variants AND the defined CDG enzyme activity consistent with a diagnosis of the CDG other than PMM2 CDG.
- If not enrolling directly from a parent study (i.e., more than 28 days from Final Treatment visit in a parent study to date of consent), has an active infection requiring parenteral antibiotics, antivirals, or antifungals or treatment with systemic steroids within 7 days prior to Screening;
- ALT or AST >3× ULN OR total bilirubin >2× ULN or INR >1.5 (if no anti-coagulation treatment) or INR > 4 (if participant on anti-coagulation treatment) considered clinically significant;
- Has a history of liver transplant;
- Has a history of drug or alcohol use disorder within the 12 months prior to Screening;
- If not enrolling directly from a parent study (i.e., if more than 28 days from Final Treatment visit in a parent study to date of consent), has had a major surgical procedure within 30 days prior to Screening;
- Has laboratory value(s) outside the laboratory reference range considered clinically significant and not related to PMM2-CDG;
- If female, has a positive serum pregnancy test during Screening.
- If female, and breastfeeding.
- Is currently participating in another interventional clinical study or has completed another clinical study with an investigational drug or device (other than GLM101) within 30 days or 5 half-lives before GLM101 infusion.
- Has a hypersensitivity to anti-histamine pre-medication.
- Has a history of a severe allergic reaction to any drug or excipients of GLM101 (as listed in the GLM101 IB);
- If not enrolling directly from a parent study (i.e., if more than 28 days from Final Treatment visit in a parent study to date of consent), has serology positive for hepatitis B surface antigen or hepatitis C antibody during Screening;
- Has a QTc ≥ 450 ms, or other clinically significant ECG abnormalities;
- Has uncontrolled cardiovascular, hepatic, pulmonary, gastro-intestinal, endocrine, metabolic, ophthalmologic, immunologic, psychiatric or other significant disease;
- Weight exceeds 120 kg.
- Persons who have been committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
- Participant is unwilling or unable to comply with scheduled visits, study drug administration plan, laboratory tests, other study procedures, and study restrictions.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: 30 mg/kg GLM101
GLM101 IV infusions, given weekly |
GLM101 IV infusion |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Evaluate long-term safety
Časové okno: From enrollment to end of treatment up to 4 years
|
Number of participants with treatment related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 |
From enrollment to end of treatment up to 4 years
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Evaluate changes in ataxia using International Cooperative Ataxia Rating Scale (ICARS)
Časové okno: From enrollment, at 3 months, 6 months and annually to end of treatment up to 4 years
|
The scale is scored out of 100 with 19 items and 4 subscales of postural and gait disturbances, limb ataxia, dysarthria, and oculomotor disorders. Higher scores indicate higher levels of impairment. |
From enrollment, at 3 months, 6 months and annually to end of treatment up to 4 years
|
|
Maximum observed plasma concentration (Cmax)
Časové okno: From enrollment to end of treatment up to 4 years
|
Assessment of the pharmacokinetics (PK) of GLM101 |
From enrollment to end of treatment up to 4 years
|
|
Time to maximum observed plasma concentration (Tmax)
Časové okno: From enrollment to end of treatment up to 4 years
|
Assessment pharmacokinetics (PK) of GLM101 |
From enrollment to end of treatment up to 4 years
|
|
Area under the plasma concentration vs. time curve (AUC)
Časové okno: From enrollment to end of treatment up to 4 years
|
Assessment of the pharmacokinetics (PK) of GLM101 |
From enrollment to end of treatment up to 4 years
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Ředitel studie: Chief Medical Officer, Glycomine, Inc.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- GLM101-007
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .